Drug Trial Radar · NCT00548509
The Effect of Vitamin K2 on Bone Turnover
Last checked: Nov 20, 2026Latest source record: Oct 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Feb 1, 2002
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Oct 24, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 49 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the effect of menatetrenone on bone turnover in postmenopausal patients with osteoporosis. One month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin. Moderate increases of bone resorption and formation markers were observed after 6 months. These changes may contribute to fracture prevention in patients with osteoporosis.
Conditions
- Osteoporosis
Interventions
Menatetrenone (Vitamin K2)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Gamma-carboxylation
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Kumagaya-shi, Saitama, Japan
Site not named
Hachioji-shi, Tokyo, Japan
Site not named
Setagaya-Ku, Tokyo, Japan
Site not named
Nishiyatsushiro-Gun, Yamanashi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.